Anticoagulant-induced Bleeding: Clinical Trials

34 trials for Anticoagulant-induced Bleeding, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 completed, 10 unknown, 2 recruiting, 2 terminated. 9 Not applicable, 5 Phase 2, 5 Phase 4, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Not applicable9Completed 5, Not yet recruiting 1, Recruiting 1, Terminated 1, Unknown 1
Phase 25Completed 4, Withdrawn 1
Phase 45Completed 1, Enrolling by invitation 1, Recruiting 1, Terminated 1, Unknown 1
Phase 11Completed 1
Phase 31Completed 1

Follow Anticoagulant-induced Bleeding: new trials by email Literature Review of Anticoagulant-induced Bleeding trials Research Report on Anticoagulant-induced Bleeding

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Peri-procedural Management of Direct Oral Anticoagulants for Central VENOus Catheters in CAncer Patients With Venous Thromboembolism or Atrial Fibrillation Pilot Study
Continued DOAC, Interrupted DOAC - Anticoagulant-induced Bleeding, Direct Oral Anticoagulant
Not applicableNot yet recruitingUniversity Health Network, Toronto102025-09-012025-03-20
Long-term Results of Percutaneous Left Atrial Closure at Brest University Hospital (CLAPOT)
Atrial Fibrillation, Cardioembolic Stroke
UnknownUniversity Hospital, Brest1202024-02-012024-08-09
Anticoagulant-associated Intracranial Hemorrhage
Anticoagulant - Anticoagulant-induced Bleeding, Intracranial Hemorrhages
UnknownEl Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez12002023-08-092023-12-13
Optimization of Management in Patients With Cardiovascular Disease After Lower Limb Joint Replacement
No intervention - Thromboembolism, Anticoagulant-induced Bleeding
Active not recruitingI.M. Sechenov First Moscow State Medical University17332023-01-152026-05-14
Anticoagulation With Enhanced Gastrointestinal Safety
Clinician Notification with Nurse Facilitation (CNNF), Wait list control - Upper Gastrointestinal Bleeding, Peptic Ulcer Hemorrhage
Not applicableCompletedUniversity of Michigan3412022-10-052024-04-30
Strategies for Anticoagulation During Venovenous ECMO
Low intensity anticoagulation, Moderate Intensity Anticoagulation - Acute Hypoxemic Respiratory Failure, Anticoagulant-induced Bleeding
Not applicableCompletedVanderbilt University Medical Center262022-05-122025-06-18
Anticoagulation After GI Bleeding Pilot Study and Registry
Restart DOAC within 7 days of clinical hemostasis after GI bleeding, Restart DOAC between 7 to 14 days of clinical hemostasis after GI bleeding - GastroIntestinal Bleeding, Anticoagulant-induced Bleeding
Not applicableRecruitingOttawa Hospital Research Institute1002022-03-312026-10-02
DOAC Versus VKA After Cardiac Surgery
Warfarin, Dabigatran, Rivaroxaban - Anticoagulant-induced Bleeding
Phase 2WithdrawnLaval University2022-03-092023-03-13
Vitamin K Antagonist Versus Direct Oral Anticoagulant Treatments in Hemophilia
Vitamin K Antagonist - Drug - Hemophilia A, Hemophilia B
CompletedGroupe Maladies hémorragiques de Bretagne542021-06-012023-04-07
Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients
Direct oral anticoagulant - Pulmonary Embolism, Venous Thromboembolism
UnknownPeking Union Medical College Hospital3002021-04-012024-01-08
Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty
Warfarin, Dabigatran, Rivaroxaban - Atrial Fibrillation, Frailty
UnknownBrigham and Women's Hospital10000002021-03-302021-05-07
Management of Anticoagulants and Antithrombotics in Patients With CSDH
CSDH evacuation - Chronic Subdural Hematoma, Anticoagulant-induced Bleeding
UnknownUniversity Hospital of Ferrara4002021-02-202022-11-03
Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events
Rivaroxaban 20 MG [Xarelto], Aspirin 300mg, Acenocoumarol Oral Tablet - Venous Thromboembolism, Anticoagulant-induced Bleeding
Phase 2 / Phase 3CompletedInstituto Mexicano del Seguro Social582021-01-032022-08-25
Perioperative Management of Factor Xa Inhibitors
Factor Xa Inhibitor - Atrial Fibrillation, Anticoagulant-induced Bleeding
Not applicableCompletedSeoul National University Hospital25002020-08-042026-08-21
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
Rivaroxaban, Placebo - Pulmonary Embolism, Embolism
Phase 4RecruitingDrahomir Aujesky2762020-05-152026-05-22
Safety of Anticoagulant Therapy After Endoscopic Treatment
nadroparin calcium-warfarin sequential anticoagulation - Cirrhosis, Portal Vein Thrombosis
Phase 4CompletedQilu Hospital of Shandong University862020-02-012022-10-12
Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)
Antithrombotic Agent - Atrial Fibrillation, Myocardial Infarction
UnknownScientific Institute San Raffaele15002020-01-252020-03-26
Comparing TR Band to Statseal in Conjunction With TR Band II
Statseal with TR Band, TR band only - Arterial Occlusion, Cardiovascular Diseases
Not applicableTerminatedVA Long Beach Healthcare System4432019-10-102024-11-19
Geriatric Head Trauma Short Term Outcomes Project
Head Injury, Anticoagulant-induced Bleeding
CompletedFlorida Atlantic University53872019-08-152022-08-03
AI-based Social Software to Manage wARfarin Therapy
AI-based social software management model, Human-based social software management model - Anticoagulant-induced Bleeding, Warfarin Sodium Causing Adverse Effects in Therapeutic Use
Not applicableUnknownWuhan Asia Heart Hospital5002019-05-012019-03-12

Showing 20 of 34. Sign in to see all of them.

Narrower conditions

Atrial Fibrillation (7)  ·  Hemorrhage (7)  ·  Venous Thromboembolism (5)  ·  Cardiovascular Diseases (4)  ·  Thromboembolism (4)  ·  Coronary Artery Disease (3)  ·  Hematoma (3)  ·  Intracranial Hemorrhages (3)  ·  Pulmonary Embolism (3)  ·  Thrombosis (3)  ·  Venous Thrombosis (3)  ·  Arterial Occlusive Diseases (2)  ·  Atherosclerosis (2)  ·  Cerebral Hemorrhage (2)  ·  Gastrointestinal Hemorrhage (2)

Broader conditions

Pathologic Processes (24)  ·  Pathological Conditions, Signs and Symptoms (24)  ·  Vascular Diseases (21)  ·  Cardiovascular Diseases (18)  ·  Embolism and Thrombosis (11)  ·  Heart Diseases (11)  ·  Hemorrhage (8)  ·  Arrhythmias, Cardiac (7)  ·  Nervous System Diseases (7)  ·  Brain Diseases (5)  ·  Central Nervous System Diseases (5)  ·  Cerebrovascular Disorders (5)  ·  Digestive System Diseases (4)  ·  Myocardial Ischemia (4)  ·  Thromboembolism (4)

Interventions

Rivaroxaban (7)  ·  Dabigatran (4)  ·  Warfarin (3)  ·  apixaban (3)  ·  edoxaban (3)  ·  Aspirin (2)  ·  Enoxaparin (2)  ·  Fibrinolytic Agents (2)  ·  Heparin (2)  ·  N(4)-oleylcytosine arabinoside (2)  ·  Acenocoumarol (1)  ·  Anticoagulants (1)  ·  Anticoagulation Reversal (1)  ·  Dental Scaling (1)  ·  Factor Xa Inhibitors (1)

Sponsors

University of Trieste (2)  ·  VA Long Beach Healthcare System (2)  ·  Albert Einstein College of Medicine (1)  ·  Arianna Anticoagulazione Foundation (1)  ·  Brigham and Women's Hospital (1)  ·  Drahomir Aujesky (1)  ·  El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (1)  ·  First Affiliated Hospital Xi'an Jiaotong University (1)  ·  Florida Atlantic University (1)  ·  Gines Escolar (1)  ·  Groupe Maladies hémorragiques de Bretagne (1)  ·  Hospital Civil de Guadalajara (1)  ·  I.M. Sechenov First Moscow State Medical University (1)  ·  Instituto Mexicano del Seguro Social (1)  ·  Laval University (1)

Countries

United States (9)  ·  Italy (6)  ·  China (5)  ·  Canada (3)  ·  France (3)  ·  Mexico (3)  ·  Sweden (2)  ·  Belgium (1)  ·  Denmark (1)  ·  Netherlands (1)  ·  Norway (1)  ·  Russia (1)  ·  South Korea (1)  ·  Spain (1)  ·  Switzerland (1)

Top investigators

Federico Berton, Dr. (2)  ·  Fulvia Costantinides, Dr. (2)  ·  Roberto Di Lenarda, Prof. (2)  ·  Antonio Arcadipane, MD (1)  ·  Arnold H Seto, M.D. (1)  ·  Chao You, PhD (1)  ·  Claudia Vanessa Cano Nigenda, MD (1)  ·  Craig S Anderson, PhD (1)  ·  Dae Hyun Kim, MD, MPH, ScD (1)  ·  Deborah M Siegal, MD MSc (1)  ·  Drahomir Aujesky, Prof. MD MSc (1)  ·  Erika Visintini, Dr. (1)  ·  Eue-Keun Choi, MD, PhD (1)  ·  Gaetano Castronovo, Dr. (1)

Results publications

PMID 17446349, PMID 19427958, PMID 21207349, PMID 22127656, PMID 22315271, PMID 23407628, PMID 24455237, PMID 25440361, PMID 26364029, PMID 28376486, PMID 28581331, PMID 28760063, PMID 28860793, PMID 29769165, PMID 30144419, PMID 30928922, PMID 30939954, PMID 31983518, PMID 32156512, PMID 32980294, PMID 33099283, PMID 33444199, PMID 34022160, PMID 34022170, PMID 34929690, PMID 34930428, PMID 35450681, PMID 35783649, PMID 36063792, PMID 36244055, PMID 37245517, PMID 38394387, PMID 38774425, PMID 38842448, PMID 39106508, PMID 39271405, PMID 39700102, PMID 40081660, PMID 40221663, PMID 40541207, PMID 40927652, PMID 40939125, PMID 41291481, PMID 41722271, PMID 41855454, PMID 41873543, PMID 42848972

NIH funding

2019 (1), K23DK118179 (1)